Marek Brzosko

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

Joel M. Kremer, Ricardo Blanco, Marek Brzosko et al. · Arthritis & Rheumatism · 2010 · 414 citations

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

Won Park, Dae‐Hyun Yoo, Pedro C. Miranda et al. · Annals of the Rheumatic Diseases · 2016 · 229 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis

Andrzej Pawlik, Lidia Ostanek, Iwona Brzosko et al. · Arthritis Research & Therapy · 2003 · 123 citations · Full text

Life Sciences, Immunology, Internal Medicine +13

Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results

Roy Fleischmann, Anne-Marie Halland, Marek Brzosko et al. · The Journal of Rheumatology · 2013 · 123 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16

Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib

R. Lehmann, Marek Brzosko, Petr Kopsa et al. · Current Medical Research and Opinion · 2005 · 73 citations

Medicine, Orthopaedic Surgery, Pharmacotherapy +15